Related Experiment Video

Updated: Jul 2, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute

Yongzheng Jiang1, Shengqi Jia2, Dingyuan Tian3

  • 1Department of Cardiology, Affiliated Hospital of Hebei University, 212 Yuhua East Road, Baoding, 071000, China.

Cardiovascular Drugs and Therapy
|July 1, 2026
PubMed

Insights

Early dapagliflozin initiation in heart failure patients after myocardial infarction improved cardiac remodeling and reduced hospitalizations. Further trials are needed to confirm these findings for acute myocardial infarction (AMI) patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute myocardial infarction (AMI) complicated by heart failure presents significant challenges.
  • Left ventricular remodeling is a key determinant of outcomes post-AMI.
  • Understanding interventions that mitigate adverse remodeling is crucial.

Purpose of the Study:

  • To investigate the association between early in-hospital dapagliflozin initiation and left ventricular remodeling.
  • To assess the impact of dapagliflozin on cardiac structure and function in revascularized AMI patients with heart failure.

Main Methods:

  • Retrospective cohort study of 266 revascularized AMI patients with heart failure.
  • Patients stratified by in-hospital dapagliflozin initiation (10 mg daily) post-hemodynamic stabilization.
  • Inverse probability of treatment weighting and generalized estimating equations used to analyze changes in left ventricular end-diastolic volume index (LVEDVI) over 12 months.

Main Results:

  • Early dapagliflozin initiation showed greater reductions in ventricular volumes (LVEDVI, LVMI) and improved left ventricular ejection fraction (LVEF) recovery.
  • No significant difference in functional status (NYHA class) between groups.
  • A trend towards reduced major adverse cardiovascular events, primarily driven by fewer heart failure rehospitalizations.

Conclusions:

  • In-hospital dapagliflozin initiation in AMI patients with heart failure is linked to favorable cardiac remodeling.
  • Associated with a reduction in heart failure rehospitalizations.
  • These findings support the need for randomized controlled trials to confirm efficacy.
Abstract

Keywords:
Acute myocardial infarctionDapagliflozinGeneralized Estimating EquationsHeart failureReverse remodeling

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...